ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Session » Muscle Biology, Myositis and Myopathies Poster III: Treatment and Classification Criteria

Date: Tuesday, October 23, 2018

Time: 9:00AM-11:00AM

Meeting: 2018 ACR/ARHP Annual Meeting

9:00AM-11:00AM
Abstract Number: 2295
Classification of Idiopathic Inflammatory Myopathies: Assessment of 123 Patients According to 2017 Acr/EULAR Criteria Followed up By a Single Center from Turkey
9:00AM-11:00AM
Abstract Number: 2298
Developing a Classification Criteria for Cutaneous Dermatomyositis Utilizing the Delphi Technique
9:00AM-11:00AM
Abstract Number: 2285
Factors Associated with Corticosteroid Discontinuation, Complete Clinical Response and Remission in Patients with Juvenile Dermatomyositis
9:00AM-11:00AM
Abstract Number: 2289
Granulomatous Myositis: Heterogeneity and Response to Treatment
9:00AM-11:00AM
Abstract Number: 2294
Improving EULAR/Acr Classification Criteria for Idiopathic Inflammatory Myopathies
9:00AM-11:00AM
Abstract Number: 2287
Interim Results of an Open-Label Study Assessing Efficacy and Safety of Adrenocorticotropic Hormone Gel for Treatment of Refractory Cutaneous Manifestations of Dermatomyositis
9:00AM-11:00AM
Abstract Number: 2290
Long Term Follow-up Results of Myositis Patients Treated with H. P. Acthar Gel
9:00AM-11:00AM
Abstract Number: 2291
Longitudinal Course of the Disease in Anti-Mi2 Patients: More Intense Muscle Weakness, Good Response to Treatment and Progressive Reduction of Autoantibody Titers
9:00AM-11:00AM
Abstract Number: 2286
Myositis and Fasciitis By Magnetic Resonance Imaging in Recent-Onset Polymyalgia Rheumatica and Effect of Tocilizumab Therapy
9:00AM-11:00AM
Abstract Number: 2296
Novel Classification of Idiopathic Inflammatory Myopathies Based on Distinctive Features and Autoantibodies: Analysis of 67 Korean Patients
9:00AM-11:00AM
Abstract Number: 2297
Performance of the New EULAR/Acr Classification Criteria for Idiopathic Inflammatory Myopathies (IIM) in a Large Monocentric IIM Cohort
9:00AM-11:00AM
Abstract Number: 2288
Preexisting Anti-Acetylcholine Receptor Autoantibodies and B Cell Lymphopenia Are Associated with the Development of Myositis in Thymoma Patients Treated with Avelumab, an Immune Checkpoint Inhibitor Targeting Programmed Death-Ligand 1
9:00AM-11:00AM
Abstract Number: 2284
Safety and Efficacy of Lenabasum in Refractory Skin-Predominant Dermatomyositis Subjects Treated on an Open-Label Extension of Trial JBT101-DM-001
9:00AM-11:00AM
Abstract Number: 2293
Subcutaneous Intravenous Immunoglobulins in Idiopathic Inflammatory Myopathies: Analysis of a Monocentric Cohort
9:00AM-11:00AM
Abstract Number: 2292
The Predictive Risk Factors for Opportunistic Infection during Immunosuppressive Therapy for Polymyositis/Dermatomyositis

« View all sessions from this meeting

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology